StockData
Altimmune, Inc. logo

Altimmune, Inc. (ALT) stock

ALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/30
$1.53−0.03 (-1.92%)

Close on Nov 17, 2026Market cap $297.61MP/E –Yield –

Altimmune total assets

Total assets on the balance sheet at the end of each period.

Altimmune's total assets was $527.21M at Jun 30, 2026. For fiscal 2025 it was $279.93M, up 100.9% from the year before. Over ten years it grew 30.3% a year on average. The highest annual figure on record is $279.93M in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$279.93M+100.9%
FY2024Dec 31, 2024$139.31M-33.9%
FY2023Dec 31, 2023$210.64M+1.8%
FY2022Dec 31, 2022$206.93M-5.5%
FY2021Dec 31, 2021$218.87M-10.7%
FY2020Dec 31, 2020$245.12M+353.4%
FY2019Dec 31, 2019$54.06M-1.3%
FY2018Dec 31, 2018$54.75M-13.1%
FY2017Dec 31, 2017$63.03M+64.1%
FY2016Dec 31, 2016$38.40M+93.3%
FY2015Dec 31, 2015$19.86M-9.6%
FY2014Dec 31, 2014$21.98M+28.2%
FY2013Dec 31, 2013$17.14M-24.6%
FY2012Dec 31, 2012$22.74M-0.3%
FY2011Dec 31, 2011$22.80M-16.2%
FY2010Dec 31, 2010$27.20M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$527.21M+177.0%
Q1 FY2026Mar 31, 2026$335.63M+113.4%
Q4 FY2025Dec 31, 2025$279.93M+100.9%
Q3 FY2025Sep 30, 2025$218.45M+47.7%
Q2 FY2025Jun 30, 2025$190.35M+9.8%
Q1 FY2025Mar 31, 2025$157.26M-16.5%
Q4 FY2024Dec 31, 2024$139.31M-33.9%
Q3 FY2024Sep 30, 2024$147.86M-11.2%
Q2 FY2024Jun 30, 2024$173.35M-5.4%
Q1 FY2024Mar 31, 2024$188.36M+0.7%
Q4 FY2023Dec 31, 2023$210.64M+1.8%
Q3 FY2023Sep 30, 2023$166.57M-26.1%
Q2 FY2023Jun 30, 2023$183.32M-12.7%
Q1 FY2023Mar 31, 2023$187.08M-9.0%
Q4 FY2022Dec 31, 2022$206.93M-5.5%
Q3 FY2022Sep 30, 2022$225.28M-4.9%
Q2 FY2022Jun 30, 2022$209.91M-18.4%
Q1 FY2022Mar 31, 2022$205.66M-22.2%
Q4 FY2021Dec 31, 2021$218.87M-10.7%
Q3 FY2021Sep 30, 2021$236.91M+1.7%
Q2 FY2021Jun 30, 2021$257.26M+150.9%
Q1 FY2021Mar 31, 2021$264.25M+387.2%
Q4 FY2020Dec 31, 2020$245.12M+353.4%
Q3 FY2020Sep 30, 2020$233.00M+313.2%
Q2 FY2020Jun 30, 2020$102.54M+65.5%
Q1 FY2020Mar 31, 2020$54.23M-17.0%
Q4 FY2019Dec 31, 2019$54.06M-1.3%
Q3 FY2019Sep 30, 2019$56.39M+6.7%
Q2 FY2019Jun 30, 2019$61.98M+19.0%
Q1 FY2019Mar 31, 2019$65.37M+7.4%
Q4 FY2018Dec 31, 2018$54.75M-13.1%
Q3 FY2018Sep 30, 2018$52.86M-28.9%
Q2 FY2018Jun 30, 2018$52.10M-42.6%
Q1 FY2018Mar 31, 2018$60.87M+193.6%
Q4 FY2017Dec 31, 2017$63.03M+64.1%
Q3 FY2017Sep 30, 2017$74.35M-47.1%
Q2 FY2017Jun 30, 2017$90.84M–
Q1 FY2017Mar 31, 2017$20.73M–
Q4 FY2016Dec 31, 2016$38.40M–
Q3 FY2016Sep 30, 2016$140.54M–

More Altimmune figures

See a number that looks wrong?